EIF2AK2

Across TCGA pan-cancer cohorts, EIF2AK2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of EIF2AK2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where EIF2AK2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types EIF2AK2 is over-expressed in tumor.

HNSC, COAD, and CCRCC are the cancer types where EIF2AK2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EIF2AK2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.858	<.001	11	view →
COAD	Female	III,IV	+0.464	<.001	11	view →
CCRCC	Male	III,IV	+0.249	<.001	11	view →
LSCC	Male	II,III,IV	+0.622	<.001	9	view →
PDAC	Male	All	+0.583	<.001	9	view →
LUAD	Female	II,III,IV	+0.321	<.001	9	view →
OV	All	All	+0.470	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

EIF2AK2–HNSC

Open the HNSC breakdown →